MX2013010794A - Sustancia inmunologica terapeutica rapida y prolongada. - Google Patents
Sustancia inmunologica terapeutica rapida y prolongada.Info
- Publication number
- MX2013010794A MX2013010794A MX2013010794A MX2013010794A MX2013010794A MX 2013010794 A MX2013010794 A MX 2013010794A MX 2013010794 A MX2013010794 A MX 2013010794A MX 2013010794 A MX2013010794 A MX 2013010794A MX 2013010794 A MX2013010794 A MX 2013010794A
- Authority
- MX
- Mexico
- Prior art keywords
- rapid
- pathogen
- prolonged
- defective adenovirus
- therapeutic
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title abstract 3
- 244000052769 pathogen Species 0.000 abstract 4
- 241000701161 unidentified adenovirus Species 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 230000001681 protective effect Effects 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 244000052613 viral pathogen Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención muestra que la administración intranasal de partículas de adenovirus defectuosas en E1/E3 pueden conferir protección rápida y amplia contra patógenos virales y bacterianos en una variedad de ámbitos de enfermedad. Las respuestas protectoras duran por muchas semanas en un régimen de dosis única en modelos en animales. Cuando se inserta un gen de antígeno derivado de patógeno en el genoma de adenovirus defectuoso en E1/E3, la inmunidad protectora inducida por antígeno contra el patógeno específico es inducida antes de que decline por eliminación la respuesta protectora mediada por adenovirus, y por lo tanto confiere protección rápida, prolongada y sin protecciones contra patógenos. Además del adenovirus defectuoso en E1/E3, también se pueden desarrollar otros vectores no replicantes biomanipulados que codifican para antígenos derivados de patógeno, en una generación nueva de sustancias inmunológicas terapéuticas rápidas y prologandas (RAPIT).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161454819P | 2011-03-21 | 2011-03-21 | |
US201161568054P | 2011-12-07 | 2011-12-07 | |
PCT/US2012/029927 WO2012129295A1 (en) | 2011-03-21 | 2012-03-21 | Rapid and prolonged immunologic-therapeutic |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010794A true MX2013010794A (es) | 2014-03-12 |
MX348172B MX348172B (es) | 2017-06-02 |
Family
ID=46879727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010794A MX348172B (es) | 2011-03-21 | 2012-03-21 | Sustancia inmunologica terapeutica rapida y prolongada. |
Country Status (9)
Country | Link |
---|---|
US (2) | US9175310B2 (es) |
EP (3) | EP3763385A1 (es) |
JP (4) | JP6075734B2 (es) |
KR (4) | KR102104650B1 (es) |
CA (1) | CA2829916C (es) |
DK (2) | DK3205353T3 (es) |
ES (2) | ES2645156T3 (es) |
MX (1) | MX348172B (es) |
WO (1) | WO2012129295A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10183069B2 (en) * | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
EP3041503A4 (en) * | 2013-09-06 | 2017-06-07 | Altimmune Inc. | Methods and compositions for viral vectored vaccines |
US11571472B2 (en) | 2014-06-13 | 2023-02-07 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
MA50278A (fr) | 2017-04-18 | 2020-02-26 | Alnylam Pharmaceuticals Inc | Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb) |
CN111315407B (zh) * | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
WO2020182322A1 (en) * | 2019-03-14 | 2020-09-17 | Om Pharma Sa | Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders |
US20210260180A1 (en) * | 2020-02-14 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
CN117412769A (zh) * | 2021-01-15 | 2024-01-16 | 美国政府(由卫生和人类服务部的部长所代表) | 具有复制能力的4型腺病毒sars-cov-2疫苗及其用途 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5578308A (en) | 1990-02-12 | 1996-11-26 | Capiau; Carine | Glutaraldehyde and formalin detoxified bordetella toxin vaccine |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
WO1992015689A1 (en) | 1991-03-05 | 1992-09-17 | The Wellcome Foundation Limited | Expression of recombinant proteins in attenuated bacteria |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5989561A (en) | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
US5863542A (en) | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
JPH06327480A (ja) | 1993-05-20 | 1994-11-29 | Mitsubishi Petrochem Co Ltd | プラスミドの自律複製を司る機能に関与する遺伝子を含むdna断片 |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5976552A (en) | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
EP0979101B1 (en) | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6716823B1 (en) * | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US6348450B1 (en) * | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
AU4004699A (en) | 1998-05-15 | 1999-12-06 | Quark Biotech, Inc. | Mechanical stress induced genes, expression products therefrom, and uses thereof |
US20050271689A1 (en) * | 2003-07-11 | 2005-12-08 | Chun-Ming Huang | Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
MXPA01011137A (es) * | 1999-05-03 | 2003-07-14 | Uab Research Foundation | Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos. |
US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
NZ530245A (en) * | 2001-06-22 | 2007-04-27 | Wistar Inst | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
US7569217B2 (en) | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
FR2855758B1 (fr) * | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
CA2880061C (en) * | 2004-01-23 | 2018-03-13 | Agostino Cirillo | Chimpanzee adenovirus vaccine carriers |
US7566454B2 (en) * | 2005-02-24 | 2009-07-28 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
KR20080052509A (ko) * | 2005-04-11 | 2008-06-11 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 | 유행성 독감 바이러스에 대한 백신 |
CN101248186A (zh) | 2005-05-23 | 2008-08-20 | 瓦克辛公司 | 不含腺病毒的重组腺病毒载体的快速生产 |
EP3061462B1 (en) * | 2007-07-02 | 2019-02-27 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
WO2010037027A2 (en) * | 2008-09-26 | 2010-04-01 | Auburn University | Immunization of avians by mucosal administration of non-replicating vectored vaccines |
US9095546B2 (en) * | 2009-07-20 | 2015-08-04 | National Health Research Institutes | Human respiratory syncytial virus (RSV) vaccine |
US9911066B2 (en) | 2013-12-01 | 2018-03-06 | Zoe JEWELL | Classification system for similar objects from digital images |
JP2016143853A (ja) | 2015-02-05 | 2016-08-08 | 富士通株式会社 | 積層型半導体装置 |
-
2012
- 2012-03-21 KR KR1020137027573A patent/KR102104650B1/ko active IP Right Grant
- 2012-03-21 US US13/426,037 patent/US9175310B2/en active Active
- 2012-03-21 DK DK17162446.3T patent/DK3205353T3/da active
- 2012-03-21 JP JP2014501205A patent/JP6075734B2/ja active Active
- 2012-03-21 EP EP20183446.2A patent/EP3763385A1/en not_active Withdrawn
- 2012-03-21 CA CA2829916A patent/CA2829916C/en active Active
- 2012-03-21 ES ES12760743.0T patent/ES2645156T3/es active Active
- 2012-03-21 ES ES17162446T patent/ES2861576T3/es active Active
- 2012-03-21 MX MX2013010794A patent/MX348172B/es active IP Right Grant
- 2012-03-21 EP EP17162446.3A patent/EP3205353B1/en active Active
- 2012-03-21 DK DK12760743.0T patent/DK2688588T3/da active
- 2012-03-21 EP EP12760743.0A patent/EP2688588B1/en active Active
- 2012-03-21 WO PCT/US2012/029927 patent/WO2012129295A1/en active Application Filing
- 2012-03-21 KR KR1020207000452A patent/KR20200008014A/ko not_active IP Right Cessation
- 2012-03-21 KR KR1020207011422A patent/KR20200044990A/ko not_active IP Right Cessation
- 2012-03-21 KR KR1020227006180A patent/KR20220047790A/ko not_active Application Discontinuation
-
2013
- 2013-12-30 US US14/143,104 patent/US9605275B2/en active Active
-
2016
- 2016-09-30 JP JP2016193411A patent/JP6177981B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-11 JP JP2017135272A patent/JP2017186369A/ja active Pending
-
2019
- 2019-03-05 JP JP2019039722A patent/JP6943908B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6075734B2 (ja) | 2017-02-08 |
CA2829916C (en) | 2019-08-20 |
KR20200008014A (ko) | 2020-01-22 |
KR20220047790A (ko) | 2022-04-19 |
EP2688588B1 (en) | 2017-08-09 |
JP2019081806A (ja) | 2019-05-30 |
EP3205353A1 (en) | 2017-08-16 |
US9175310B2 (en) | 2015-11-03 |
DK2688588T3 (da) | 2017-11-13 |
KR20140123403A (ko) | 2014-10-22 |
ES2645156T3 (es) | 2017-12-04 |
WO2012129295A1 (en) | 2012-09-27 |
DK3205353T3 (da) | 2021-04-06 |
MX348172B (es) | 2017-06-02 |
EP3205353B1 (en) | 2021-01-13 |
KR102104650B1 (ko) | 2020-04-24 |
JP2017186369A (ja) | 2017-10-12 |
US20120276138A1 (en) | 2012-11-01 |
EP3763385A1 (en) | 2021-01-13 |
JP6177981B2 (ja) | 2017-08-09 |
JP2014513067A (ja) | 2014-05-29 |
JP6943908B2 (ja) | 2021-10-06 |
KR20200044990A (ko) | 2020-04-29 |
US20140141041A1 (en) | 2014-05-22 |
ES2861576T3 (es) | 2021-10-06 |
EP2688588A4 (en) | 2014-09-10 |
JP2017008100A (ja) | 2017-01-12 |
CA2829916A1 (en) | 2012-09-27 |
US9605275B2 (en) | 2017-03-28 |
EP2688588A1 (en) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013010794A (es) | Sustancia inmunologica terapeutica rapida y prolongada. | |
WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
MX361893B (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. | |
MX346245B (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
MX350274B (es) | Vacunas para hsv-2. | |
MX2008016036A (es) | Vacuna viral recombinante. | |
ZA201109444B (en) | Vaccines against herpes simplex virus type 2:compositions and methods for eliciting an immune response | |
HK1246318A1 (zh) | 乙型肝炎病毒核心蛋白和表面抗原蛋白以及包含其的疫苗 | |
JP2011136997A5 (es) | ||
WO2012170765A3 (en) | Cmv glycoproteins and recombinant vectors | |
MX2010007461A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
WO2012064960A3 (en) | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination | |
MX346596B (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
PL2658570T3 (pl) | Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b | |
MD4481B1 (ro) | Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV | |
PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
MX2022000718A (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9. | |
NZ700470A (en) | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof | |
EP2643014A4 (en) | HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE | |
NZ596223A (en) | Combined measles-malaria vaccine | |
EP2353610A4 (en) | RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE | |
NZ603431A (en) | Parapoxvirus vectors containing rabies virus antigen | |
MX2016002823A (es) | Metodos y composiciones para vacunas vectorizadas virales. | |
MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC |